Who are combination of irinotecan and cisplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-of-irinotecan-and-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

combination of irinotecan and cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

combination of irinotecan and cisplatin (combination of irinotecan and cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase inhibitor and platinum-based chemotherapy. Area: Oncology.

phase 3 Topoisomerase inhibitor and platinum-based chemotherapy Topoisomerase I and DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

combination of irinotecan and cisplatin (combination of irinotecan and cisplatin) — Japan Clinical Oncology Group. Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
combination of irinotecan and cisplatin TARGET	combination of irinotecan and cisplatin	Japan Clinical Oncology Group	phase 3	Topoisomerase inhibitor and platinum-based chemotherapy	Topoisomerase I and DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topoisomerase inhibitor and platinum-based chemotherapy class)

Japan Clinical Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). combination of irinotecan and cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-of-irinotecan-and-cisplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab